3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Sarcoma
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Bevacizumab
5
pembrolizumab
3
Paclitaxel
3
fludarabine
2
Sorafenib
2
Nivolumab
2
Gemcitabine
2
Cyclophosphamide
2
Azacitidine
2
vocimagene amiretrorepvec
1
ulixertinib
1
temsirolimus
1
sacituzumab govitecan
1
ruxolitinib
1
rucaparib
1
regorafenib
1
pazopanib
1
motexafin gadolinium
1
erythromycin propionate-N-acetylcysteinate
1
durvalumab
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
capmatinib
1
belzutifan
1
aflibercept
1
abiraterone
1
Thalidomide
1
Temozolomide
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
CLR1404
×
Genitourinary
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled